Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) Earnings Dividend

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s revenue jumped 5.81% since last year same period to $1114648.92Mn in the Q1 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated -8.12% fall in its revenue since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s net profit jumped 76% since last year same period to $-24765.77Mn in the Q1 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated -123.47% fall in its net profits since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s net profit margin jumped 77.32% since last year same period to -2.22% in the Q1 2026. On a quarterly growth basis, Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has generated -125.55% fall in its net profit margins since last 3-months.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s price-to-earnings ratio after this Q1 2026 earnings stands at 42.5.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s earning per share (EPS) estimates for the current quarter stand at 0.15 - a -24.73% fall from last quarter’s estimates.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s earning per share (EPS) estimates for the current year stand at 0.15.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s return on assets (ROA) stands at 0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)’s return on equity (ROE) stands at 0.03.